Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Beijing Chest Hospital is the lead sponsor of 9 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Contezolid, Linezolid and Bedaquiline. The most-studied condition is Tuberculosis.

ClinicalTrials.gov trials by status

Recruiting111%
Not yet open111%
Active, closed111%
By invitation667%

Trials by phase

Phase 1/2222%
Phase 3222%
Observational222%
Phase 2222%
Phase 4111%

Clinical trials sponsored by Beijing Chest Hospital

9 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis NCT06403943 · ClinicalTrials.gov ↗ · Adjuvant, Treatment, Tuberculosis	Phase 4	Recruiting	2023-05	China
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort NCT07268664 · ClinicalTrials.gov ↗ · Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis	Phase 3	Not yet open	2025-12	China
Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis NCT06811012 · ClinicalTrials.gov ↗ · Tuberculosis, Bone, Joint Drugs: Contezolid, Linezolid	Phase 1/2	By invitation	2024-01	China
Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis NCT06811025 · ClinicalTrials.gov ↗ · Tuberculosis, Meningitis Drugs: Contezolid, Linezolid	Phase 1/2	By invitation	2024-02	China
Collect Data From Patients Receiving Standardized Anti-tuberculosis Therapy, Collect Monitoring Data, and Evaluate Treatment Efficacy and Potential Adverse Reactions. NCT07607288 · ClinicalTrials.gov ↗ · Therapeutic Drug Monitoring (TDM), Tuberculosis	Observational	By invitation	2021-01	China
Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease NCT07372781 · ClinicalTrials.gov ↗ · Monotherapy, Mycobacterium Abscessus Infection Drugs: Contezolid, Linezolid	Phase 2	By invitation	2026-01	China
Clinical Study on the Early Bactericidal Activity of Sitafloxacin Against Mycobacterium Abscessus Disease NCT06809413 · ClinicalTrials.gov ↗ · Fluoroquinolone, Mycobacterium Drug: Sitafloxacin	Phase 2	By invitation	2025-01	China
To Evaluate the Clinical Efficacy and Safety of Omadacycline in the Treatment of Mycobacterium Abscessus Infection. NCT07615309 · ClinicalTrials.gov ↗ · Mycobacterium Abscessus Infection, NTM Lung Infection Due to MAC	Observational	By invitation	2014-01	China
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort NCT06081361 · ClinicalTrials.gov ↗ · Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis Drugs: Bedaquiline, Clofazimine, Contezolid	Phase 3	Active, closed	2023-12	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Beijing Chest Hospital trials

10 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Contezolid4 Linezolid4 Bedaquiline1 Clofazimine1 Delamanid1 Ethambutol1 Levofloxacin1 Moxifloxacin1 Pyrazinamide1 Sitafloxacin1

Conditions in Beijing Chest Hospital trials

16 conditions

Tuberculosis5Pulmonary Tuberculosis2Mycobacterium Abscessus Infection2Bone1Joint1Meningitis1Adjuvant1Treatment1Rifampicin-resistant Tuberculosis1Therapeutic Drug Monitoring (TDM)1Rifampicin Resistant Tuberculosis1Drug-resistant Tuberculosis1Monotherapy1Fluoroquinolone1Mycobacterium1NTM Lung Infection Due to MAC1

By trial register

Register	Trials	Recruiting
Clinical trials in China	9	1

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Tuberculosis

Sponsor	Trials
Johns Hopkins University	2
National Institute of Allergy and Infectious Diseases (NIAID)	1

Sponsors with the most current trials registered for this condition.

Questions about Beijing Chest Hospital trials

How many clinical trials does Beijing Chest Hospital sponsor?

Beijing Chest Hospital is the lead sponsor of 9 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Beijing Chest Hospital trials recruiting?

Yes. 1 of its 9 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Beijing Chest Hospital testing?

Its current trials name 10 drugs and biologicals as interventions. The most frequent are Contezolid (4), Linezolid (4), Bedaquiline (1), Clofazimine (1) and Delamanid (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Beijing Chest Hospital clinical trials